APA aipamena

Alshaker, H., Wang, Q., Kawano, Y., Arafat, T., Böhler, T., Winkler, M., . . . Pchejetski, D. (2016). Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1. Oncotarget.

Chicago Style aipamena

Alshaker, Heba, Qi Wang, Yoshiaki Kawano, Tawfiq Arafat, Torsten Böhler, Mathias Winkler, Colin Cooper, and Dmitri Pchejetski. "Everolimus (RAD001) Sensitizes Prostate Cancer Cells to Docetaxel By Down-regulation of HIF-1α and Sphingosine Kinase 1." Oncotarget 2016.

MLA aipamena

Alshaker, Heba, et al. "Everolimus (RAD001) Sensitizes Prostate Cancer Cells to Docetaxel By Down-regulation of HIF-1α and Sphingosine Kinase 1." Oncotarget 2016.